These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 2465962)

  • 1. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders.
    Mörsdorf S; Köhler M; Leipnitz G; Wenzel E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):503-7. PubMed ID: 2465962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
    Gill JC; Ottum M; Schwartz B
    J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
    Rodeghiero F; Castaman G; Mannucci PM
    Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of patients with bleeding disorder to DDAVP administration.
    Chuansumrit A; Hathirat P; Pintadit P; Isarangkura P
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():174-9. PubMed ID: 7886567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis.
    Cattaneo M; Tenconi PM; Alberca I; Garcia VV; Mannucci PM
    Thromb Haemost; 1990 Nov; 64(3):358-60. PubMed ID: 2096487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.
    Ghirardini A; Mariani G; Iacopino G; Tirindelli MC; Solinas S; Moretti T
    Thromb Haemost; 1987 Oct; 58(3):896-8. PubMed ID: 3124287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.
    White B; Lawler P; Riddell A; Nitu-Whalley IC; Hermans C; Lee CA; Brown SA
    Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).
    Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E
    Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.
    Lethagen S; Harris AS; Sjörin E; Nilsson IM
    Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses.
    Mannucci PM; Vicente V; Alberca I; Sacchi E; Longo G; Harris AS; Lindquist A
    Thromb Haemost; 1987 Dec; 58(4):1037-9. PubMed ID: 3127916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of DDAVP in children with bleeding disorders.
    Ben-Ami T; Revel-Vilk S
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S41-3. PubMed ID: 23109357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease.
    Niessner H; Korninger C
    Wien Klin Wochenschr; 1983 Nov; 95(21):753-7. PubMed ID: 6424339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous administration of deamino-D-arginine-vasopressin (DDAVP) to patients with hemophilia A and von Willebrand's disease].
    Janczarski M; Ruszkowska I; Cetnarowicz H; Lopaciuk S
    Acta Haematol Pol; 1990; 21(1):16-21. PubMed ID: 2260405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.
    Rose EH; Aledort LM
    Ann Intern Med; 1991 Apr; 114(7):563-8. PubMed ID: 1900403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.